Encorafenib is approved in the United States and elsewhere in combination with binimetinib to treat BRAF V600E or V600K mutation‐positive unresectable or metastatic melanoma or in combination with cetuximab to treat BRAF V600E mutation‐positive colorectal cancer. This evidence concerns the gene BRAF and colorectal cancer.